Recent advances in immunosuppressive regimens have decreased acute cellular rejection (ACR) rates and improved intestinal and multivisceral transplant (ITx) recipient survival. We investigated the role of myeloid-derived suppressor cells (MDSCs) in ITx.
| INTRODUC TI ON
Intestinal and multivisceral transplantation (ITx) has evolved as the standard treatment for short bowel syndrome and gastrointestinal failure due to congenital and acquired diseases.
1,2 The intestinal allograft presents a formidable challenge for controlling the alloimmune response. Although the requirement for acute and chronic high-dose immunosuppression had resulted in high patient morbidity and mortality of the patients in the initial era of ITx, the introduction of induction therapy with lymphocyte-depleting agents, such as antithymocyte globulin and alemtuzumab, has markedly improved short-term graft survival and decreased the incidence and severity of acute cellular rejection (ACR). 3, 4 It has remained unclear whether the positive effects of induction therapy are simply due to decreases in T cell and/or B cell numbers or to the appearance of regulatory components that attenuate recipient responses to the graft. 5 Elucidation of these mechanisms may contribute to the development of new strategies to induce donor-specific immunological tolerance or hyporesponsiveness and improve long-term graft outcomes in ITx.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells originally characterized in rodent cancer models and patients with cancer that inhibit the immune response to tumors. 6, 7 MDSCs suppress both the proliferation and effector functions of T
cells, B cells, and natural killer cells and induce regulatory T cells via
various mechanisms. 5 During chronic inflammatory conditions, MDSCs develop from immature myeloid cells and accumulate in peripheral tissues and secondary lymphoid organs. 7 Factors inducing MDSC development include cyclooxygenase 2, prostaglandins, stem cell factor, macrophage colony-stimulating factor, interleukin (IL)-6, granulocyte/ macrophage colony-stimulating factor (GM-CSF), and vascular endothelial growth factor. 7 MDSCs play a critical role in tolerance induction in rodent transplant models, and increases in MDSCs have been reported in human renal transplant patients. [8] [9] [10] [11] However, the mechanisms promoting the development of MDSCs and their impact on alloimmune responses in clinical transplantation remain unclear. It is also unclear as to how chronic immunosuppressants administered to human transplant patients affect the differentiation of MDSCs.
We here investigated the identity and accumulation and the role of MDSCs in ITx. 
| MATERIAL S AND ME THODS

| Patients and patient characteristics
| RE SULTS
| MDSCs increase in peripheral blood mononuclear cells (PBMCs) of patients after ITx
We first investigated whether myeloid cells expressing the MDSC phenotype were present and increased in PBMCs of patients after Figure 1A ). 13 As reported in previous stud- Although levels of each of the MDSC subset were increased after ITx, they showed different patterns. Peripheral blood PMN-MDSC and e-MDSC numbers were significantly increased from pretransplant levels within 2 months after ITx ( Figure 1E, F) , and e-MDSC numbers were maintained throughout the study period ( Figure 1F ).
However, M-MDSC numbers were not significantly increased until 2 months after ITx and then increased after 2 months following ITx ( Figure 1G ). As part of the induction therapy at the time of transplant, 32 (84%) of the 37 patients were treated with alemtuzumab (Campath-1H), a humanized anti-CD52 mAb, known to be a depleting antibody, which has rapid and long-lasting effects. 18 Therefore, to investigate whether alemtuzumab affect the numbers of MDSC subsets, we assessed CD52 expression on MDSCs. We consistently observed high CD52 expression on M-MDSCs, low-absent expression on PMN-MDSCs, and heterogeneous expression on e-MDSCs across the patient samples ( Figure S1 ). Consistent with the CD52 expression, M-MDSCs were detected 4 weeks after transplant in peripheral blood of ITx patients not treated with alemtsuzumab;
however, M-MDSCs were not detected in those patients treated with alemtuzumab ( Figure S2A , B). In serial samples from ITx patients treated with alemtsuzumab, M-MDSCs were detected > 4 months after ITx when other CD52 + lineage(CD3, CD19, and CD56) + cells
were detected but not within a month after ITx ( Figure S2C ). Overall, these findings suggest that the 3 MDSC subsets increase in the peripheral blood of ITx patients after transplant and that alemtuzumab induction therapy affects the number of M-MDSCs.
Next, the MDSC-phenotype cells isolated from the peripheral blood of ITx patients were tested for the ability to suppress T cell IT039  IT044  IT057  IT060  IT067  IT068   IT069  IT071  IT056  IT061  IT063  IT066 F I G U R E 1 (Continued) and GM-CSF, were correlated significantly with MDSC numbers in PBMCs ( Figure 3A ; r = 0.6888, P = .0278 vs 0.3638 and 0.1942, respectively). In addition, we investigated the correlations of MDSC numbers in PBMCs with the days after ITx, tacrolimus trough levels and administered doses of exogenous steroids per body weight, which was normalized to a value based on the potency of each steroid drug (Table S3) . MDSC numbers were positively correlated with the exogenous steroid dose (P = .0013) and negatively with tacrolimus trough levels (P < .0001). In contrast to the significant increases in MDSC numbers in peripheral blood before versus after transplantation ( Figure 1D ), no significant correlation was observed between MDSC numbers and the days after ITx ( Figure 3B ). 
| Positive correlation between MDSCs and T regulatory cells in ITx recipients
In kidney transplant recipients, MDSCs induce FoxP3
proliferation. 19 Therefore, we investigated the relation between peripheral blood MDSCs and total regulatory CD3 + CD4 + CD25
+ CD127 − Foxp3 + T cell (Treg) numbers ( Figure 4A ). In this study,
we also dissected subsets of Tregs based on Helios expression, which was preferably expressed in naturally occurring regulatory CD4 T cells, [20] [21] [22] [23] 
| MDSCs increase in the allograft intestinal mucosa
To investigate whether MDSCs infiltrate into transplanted grafts, mononuclear cells from lamina propria components (LPCs) were analyzed by using flow cytometry. MDSC levels were low or undetectable in the allograft mucosa before implantation, but they significantly increased in percentage among CD45 + cells after ITx ( Figure   S5 , Figure 5A ). For each MDSC subset, the percentages of each of Figure 5F ). Expression of the CCR3 ligand CCL11 was low at the time of transplant and at 3 months posttransplant; however, it was markedly increased at 6 months posttransplant ( Figure 5F ). In contrast, expression levels of other CCR1, CCR2, and CCR3 ligands were as follows: CCL7, CCL16, and CCL26 levels were low in allografts before and after transplant; CCL2, CCL3, and CCL23 levels were low in allografts after transplant; and there was no significant increase in the expression levels of CCL5, CCL8, CCL13, CCL14, CCL24, and CCL28 after transplant ( Figure 5F, Figure S6 ). Graft expression of CXCR2 ligands CXCL1, CXCL2, CXCL3, and IL-8 decreased to near absent levels after transplant when tested at 3 and 6 months posttransplant.
However, graft expression of the CXCR2 ligand CXCL6 was low at the time of transplant and increased by > 3-fold by 3 months posttransplant ( Figure 5F, Figure S6) . Expression of the IFNγ inducible chemokines CXCL9, CXCL10, and CXCL11 that direct recruitment of alloantigen-primed T cells did not increase after the transplant ( Figure   S6 ). Overall, these results support a role for CCL11 and CCL15 in directing the recruitment of CCR1-and CCR3-expressing M-MDSCs and e-MDSCs and a role for CXCL6 in directing the recruitment of CXCR2-expressing PMN-MDSCs and e-MDSCs into the intestinal grafts after transplant.
| Reduced peripheral blood MDSCs during ACR
The relationship between peripheral blood MDSC numbers and occurrence of ACR was investigated in samples from 9 ITx patients with biopsy-proven ACR. The total numbers of MDSCs in PBMCs from ITx recipients with ACR was significantly lower than the numbers in patients without ACR ( Figure 6A ). ACR occurring within the first 2 months after transplant had no significant effect on the numbers of MDSCs in the peripheral blood; however, the numbers of PMN-MDSCs during ACR tended to be lower than the numbers in patients without ACR ( Figure 6B ). In addition, the numbers of M-MDSCs and e-MDSCs, but not PMN-MDSCs, significantly decreased in PBMCs from ITx patients experiencing ACR 2 months or more after transplant compared with the numbers in patients without ACR ( Figure 6B ). In terms of clinical characteristics and demographics of the ITx patients, while de novo DSAs were detected at higher rates in patients with ACR than in patients without ACR, there was no significant correlation between patients with ACR and without ACR in the other factors (Table S4) . 
| MDSCs suppress donor-specific T cellmediated damage of intestinal epithelial organoids
A critical histologic criterion for the diagnosis of ACR is > 6 apoptotic bodies/10 sequential crypts, 24, 25 which is proposed to reflect donorreactive T cell-mediated epithelial damage. 26 To directly investigate the role of MDSCs in ACR, we established an ex vivo coculture system, called "organoid formation assay," using donor-reactive T cells and intestinal epithelial organoids from donor intestinal grafts. 
Donor-reactive T cells (CFSE low T cells) and non-donor-reactive T cells (CFSE
| D ISCUSS I ON
In which we also confirmed in some of the recipients (data not shown).
In this study, we demonstrated that MP expand MDSCs from human MDSCs migrate not only to secondary lymphoid organs but also to effector sites, such as transplanted grafts and tumors, creating an immunosuppressive environment in rodent models. 7, 9, 14, [38] [39] [40] This MDSC migratory potential is essential for tolerance induction in a heart transplantation model. 9 While there is growing evidence for chemokine signaling in MDSC recruitment to tumor sites, 40 the mechanisms of MDSC migration in infection, autoimmune disease, ITx patients to investigate MDSC functions in multiple replicate of samples or in all the patients, as the patients were usually subjected to heavy immunosuppressive conditions, especially during the early time period after transplantation. Next, the sample size is relatively small, and we need to confirm our findings using a multicenter study. 
